This feature requires the newest version of Flash. You can download it here.
In This Article

Clinical Developments in Diabetes

Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you from the annual American Diabetes Association meeting in Chicago, Illinois. I would like to summarize the abstracts that I have found interesting — not everything of note, but the abstracts that I believe are clinically the most important.

A few of these are new developments, the first of which is the artificial pancreas. Everyone likes the idea of the artificial pancreas, even if the reality is still years away. I will also discuss some of the new drugs and combination drugs that incorporate different types of long-acting insulin, different types of glucagon-like peptide 1 (GLP-1) receptor agonists, and the newest class of drugs, the sodium glucose co-transporter 2 (SGLT2) inhibitors. Those are the areas which have seen the most movement in the field in terms of new data and new ideas for treating our patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.